Composition, form of production and packaging
Capsules hard gelatinous, в„–0, with the case and a cover of white color; the contents of the capsules are white or almost white powder.
1 caps.
acetyl-L-carnitine hydrochloride 295 mg
Excipients: microcrystalline cellulose - 17.8 mg, silicon dioxide colloid - 6.8 mg, crospovidone type A - 17 mg, magnesium stearate - 3.4 mg.
The composition of the capsule shell: titanium dioxide - 1.25%, gelatin - up to 100%.
10 pieces. - packings of cellular contour (1) - packs cardboard.
10 pieces. - packings cellular planimetric (2) - packs cardboard.
10 pieces. - packings cellular planimetric (3) - packs cardboard.
10 pieces. - packings cellular planimetric (4) - packs cardboard.
10 pieces. - packings cellular planimetric (5) - packs cardboard.
10 pieces. - packings cellular planimetric (6) - packs cardboard.
15 pcs. - packings of cellular contour (1) - packs cardboard.
15 pcs. - packings cellular planimetric (2) - packs cardboard.
15 pcs. - packings cellular planimetric (3) - packs cardboard.
15 pcs. - packings cellular planimetric (4) - packs cardboard.
15 pcs. - packings cellular planimetric (5) - packs cardboard.
15 pcs. - packings cellular planimetric (6) - packs cardboard.
20 pcs. - packings of cellular contour (1) - packs cardboard.
20 pcs. - packings cellular planimetric (2) - packs cardboard.
20 pcs. - packings cellular planimetric (3) - packs cardboard.
20 pcs. - packings cellular planimetric (4) - packs cardboard.
20 pcs. - packings cellular planimetric (5) - packs cardboard.
20 pcs. - packings cellular planimetric (6) - packs cardboard.
30 pcs. - packings of cellular contour (1) - packs cardboard.
30 pcs. - packings cellular planimetric (2) - packs cardboard.
30 pcs. - packings cellular planimetric (3) - packs cardboard.
30 pcs. - packings cellular planimetric (4) - packs cardboard.
30 pcs. - packings cellular planimetric (5) - packs cardboard.
30 pcs. - packings cellular planimetric (6) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2015.
PHARMACHOLOGIC EFFECT
Acetyl-L-carnitine (ALA) - a natural biologically active substance present in the body in various organs and tissues, including the central nervous system (CNS), is involved in the metabolism of fatty acids and carbohydrates. The pharmacological action of ALA is largely due to the metabolic effects of L-carnitine and the acetyl group included in its composition. Acetyl-L-carnitine is a biologically active form of L-carnitine, a key substance in the process of fat catabolism and energy production in the body. ALA is synthesized in the brain tissue, liver and kidneys from L-carnitine with the participation of the enzyme carnitine acetyltransferase.Because ALA supplies activated acetate directly to the mitochondrial structure to form acetyl CoA, participating in the cycle of tricarboxylic acids, without additional expenditure of energy, it is an easily accessible substrate for the initiation of volatile metabolic processes in the mitochondria. Due to the high-grade energy supply of the body with less oxygen consumption by tissues, ALA protects brain tissue from ischemia.
Due to its structural similarity with acetylcholine, ALA has holinomimeticheskoe action, and also exhibits neuroprotective properties. It increases the cellular concentration of aspartic and glutamic acid, as well as taurine, with prolonged use, increases the density of N-methyl-D-aspartate receptors in the hippocampus, cortex and striatum and prevents their density from decreasing under the conditions of aging. ALA enhances the effects of serotonin, and also protects brain cells from the neurotoxic effects of ammonia and glutamate.
The results of experimental studies have shown that ALA possesses anti-amiotic activity, the ability to improve learning processes, the indices of non-associative memory, to have a positive effect on mnestic functions in the experimental model of Alzheimer's disease without causing side effects of a sedative and miorelaxing nature.
ALA increases energy production, being an easily accessible substrate for the initiation of volatile metabolic processes in the mitochondria. Stimulates the synthesis of proteins and phospholipids to build membranes, improves regeneration processes. When pathology has a neuroprotective effect, especially in relation to neurons and their organelles (mitochondria), as well as neurotrophic action due to modulation of the activity of the nerve growth factor (NGF). ALA can accelerate the regeneration of nerve cells in traumatic and endocrine lesions of peripheral nerves in experimental models of polyneuropathy in diabetes.
The noticeable effect of ALA has a slowing of the processes of illumination by increasing the transport of fatty acids in the mitochondria and supporting their work at the level of the young organism.
PHARMACOKINETICS
Acetyl-L-carnitine is absorbed by active transport or simple diffusion through the mucosa of the gastrointestinal tract (under the condition of its high concentration).In most tissues, including cerebral, ALA comes from the bloodstream (except the liver and small intestine) in unchanged form. It is excreted from the body by the kidneys.
In animal studies with oral administration (500 mg / kg), the maximum concentration of the drug in the blood comes in 4 hours and is 40? M / L for 8 hours.
INDICATIONS
In complex therapy:
- initial manifestations of Alzheimer's dementia (Alzheimer's disease) and cerebrovascular dementia;
- peripheral neuropathy, incl. with diabetes mellitus;
- primary and secondary involutionary syndromes in the background of chronic ischemia;
- Decreased mental performance, to improve concentration and memory.
DOSING MODE
Inside, squeezed with enough water.
A single dose of the drug for adults is usually 1-4 capsules, the daily dose is 6-12 capsules. The course of treatment is from 1 to 4 months.
In Alzheimer's disease, the recommended dose is 1500-4000 mg per day in 2-3 divided doses. With involution syndromes - 1500-2000 mg per day. With neuropathy, the daily dose is 1500-3000 mg.
SIDE EFFECT
Allergic reactions, gastrointestinal disorders, nausea, heartburn, anxiety, there may be a specific odor in urine, sweat and smell from the mouth.
If any of the unwanted reactions listed in the manual is aggravated, or if you notice any other undesirable reactions not indicated about the instructions, inform your doctor.
CONTRAINDICATIONS
- hypersensitivity to acetylcarnitine or other components of the drug;
- Children under 18 years of age (efficacy and safety not established).
PREGNANCY AND LACTATION
Special studies on the possibility of use during pregnancy and during breastfeeding were not conducted.
The drug is used only if the intended benefit to the mother exceeds the risk to the fetus. For the duration of treatment, breastfeeding should be discontinued.
APPLICATION FOR CHILDREN
Contraindicated for children under 18 years.
SPECIAL INSTRUCTIONS
Influence on the ability to drive vehicles and perform work that requires increased attention
Does not affect the ability to drive vehicles and perform work that requires an increased concentration of attention and speed of psychomotor reactions.
OVERDOSE
Currently, cases of overdose are not registered.
DRUG INTERACTION
It is not recommended to apply simultaneously with acenocoumorol.
Care must be taken when using with warfarin simultaneously.
TERMS OF RELEASE FROM PHARMACY
On prescription.
TERMS AND CONDITIONS OF STORAGE
In a dry, protected from light place at a temperature of no higher than 25 В° C. Keep out of the reach of children. Shelf life - 2 years. Do not use after the expiry date printed on the package.
